PATENT CLAIM ANALYSIS

Application Number: 16103096
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "248000"]

Abstract:
The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Claim (Index 7):
A method for the treatment of patients who have been diagnosed with pre-diabetes or manifest type 2 diabetes comprising administering a DPP IV inhibitor of formula (I) or of formula (II) or one of the salts thereof, wherein R1 denotes ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl, (quinoxalin-6-yl)methyl, (4-methyl-quinazolin-2-yl)methyl, 2-cyano-benzyl, (3-cyano-quinolin-2-yl)methyl, (3-cyano-pyridin-2-yl)methyl, (4-methyl-pyrimidin-2-yl)methyl, or (4,6-dimethyl-pyrimidin-2-yl)methyl, and R2 denotes 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino or (2-(S)-amino-propyl)-methylamino; optionally in combination with an active substance selected from among the other antidiabetics; active substances that lower the blood sugar level; active substances that lower the lipid level in the blood; active substances that raise the HDL level in the blood; active substances that lower blood pressure; and active substances that are indicated in the treatment of atherosclerosis or obesity; wherein the risk of impaired glucose metabolism despite treatment, an elevated HbA1c value despite treatment, an impaired fasting glucose value despite treatment, the need for insulin treatment, manifest type 2 diabetes, a diabetic foot, a diabetes-associated ulcer, diabetic hyperlipidaemia, diabetic dyslipidaemia, or a micro- or macrovascular complication is reduced by the treatment.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 96.0
- Lexical Diversity: 1.44231
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['11744703', '15372702', '12673327', '14161007', '12946193']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7898874569747699
- 35 USC 102 Novelty (BERT): 0.543466103745697
- Combined Prediction Score: 0.7652453216518627
- Mean Citation Score: 380.644678
- Max Citation Score: 410.97845
- Similarity Product: 313.7188116290778

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test